Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gynecologic 1

Conditions

Multiple Myeloma 1Carcinoma, Ovarian Epithelial 1

Interventions

Specimen Handling 176Magnetic Resonance Spectroscopy 138Biopsy 102pembrolizumab 81Carboplatin 79Cisplatin 71Nivolumab 65Cyclophosphamide 64Paclitaxel 54Radiotherapy 48Gemcitabine 43durvalumab 39Doxorubicin 35Bevacizumab 34Fluorouracil 33venetoclax 32Dexamethasone 31Rituximab 30atezolizumab 29Radiation 29Capecitabine 28Lenalidomide 27Etoposide 27Prednisone 26Oxaliplatin 26Injections 26Pemetrexed 25Docetaxel 25olaparib 23fludarabine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Clarithromycin × 30 days × Clear all
NCT04302324 2026-05-20

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
11 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT07341100 2026-05-11

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡